Johnson & Johnson says long-term data boosts Icotyde for plaque psoriasis

Johnson & Johnson presented two-year results from the Phase 3 ICONIC-LEAD study of ICOTYDE® in moderate-to-severe plaque psoriasis. Data showed high skin clearance rates and sustained symptom improvement with no new safety signals. 72% of patients achieved PASI 90, and 70% achieved IGA 0/1. The study included 684 participants, with 66 adolescents. ICOTYDE is approved in the U.S., Europe, Japan, and China for psoriasis treatment.

Boston Scientific sued Johnson & Johnson subsidiary Atraverse Medical, alleging patent infringement by its Hotwire device. Boston claims Atraverse knew its actions infringed Patent '955 and seeks damages and an injunction. J&J acquired Atraverse in 2026. The electrophysiology ablation catheter market is growing at 11.1% CAGR, with J&J's Biosense Webster leading at 43.1% market share in 2025.

Johnson & Johnson (JNJ) reported that its oral psoriasis drug ICOTYDE maintained at least 72% PASI 90 response rates through week 112 in the Phase 3 ICONIC-LEAD trial. JNJ shares rose 0.40% to $257.50. Alumis (ALMS) is also developing a psoriasis drug, envudeucitinib, with a planned U.S. application in Q4 2026.

Johnson & Johnson (JNJ) reported two-year results from its Phase 3 ICONIC-LEAD study of ICOTYDE for plaque psoriasis, showing sustained skin clearance and symptom improvements. At Week 112, 72% of patients achieved PASI 90, 70% had clear/almost clear skin, and 44% had complete clearance. Safety findings were consistent with the drug's profile. JNJ is also studying ICOTYDE for other conditions. JNJ closed at $256.48, down 0.76%, and was down 0.15% in premarket trading.

Johnson & Johnson (JNJ) presented two-year Phase 3 data for ICOTYDE® (icotrokinra) at Fall Clinical Dermatology 2026, showing sustained skin clearance and safety in treating plaque psoriasis. 72% of patients achieved PASI 90, and 70% achieved IGA 0/1. The drug is approved for adults and adolescents with moderate-to-severe plaque psoriasis.

Johnson & Johnson (JNJ) reported positive two-year Phase 3 trial results for ICOTYDE, an oral peptide for plaque psoriasis, with 72% of patients achieving significant skin improvement. The company offers a 1.98% dividend yield, a 55% payout ratio, and a 4.9% 3-year dividend growth rate, but its stock is 32% overvalued relative to its GF Value. JNJ has a GF Score of 83/100, indicating strong financial health and profitability, though insider activity shows significant net selling.